Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iSpecimen (ISPC) EBITDA Margin: 2020-2025

Historic EBITDA Margin for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to -2,608.68%.

  • iSpecimen's EBITDA Margin fell 255459.00% to -2,608.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -343.99%, marking a year-over-year decrease of 25427.00%. This contributed to the annual value of -134.52% for FY2024, which is 2273.00% down from last year.
  • Latest data reveals that iSpecimen reported EBITDA Margin of -2,608.68% as of Q3 2025, which was down 1,676.42% from -146.85% recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's EBITDA Margin peaked at -31.81% during Q1 2021, and registered a low of -2,608.68% during Q3 2025.
  • Its 3-year average for EBITDA Margin is -370.23%, with a median of -126.77% in 2024.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 14,552bps in 2024, then slumped by 255,459bps in 2025.
  • Quarterly analysis of 5 years shows iSpecimen's EBITDA Margin stood at -78.26% in 2021, then skyrocketed by 595bps to -72.31% in 2022, then plummeted by 3,918bps to -111.49% in 2023, then plummeted by 29,832bps to -409.81% in 2024, then crashed by 255,459bps to -2,608.68% in 2025.
  • Its EBITDA Margin was -2,608.68% in Q3 2025, compared to -146.85% in Q2 2025 and -156.82% in Q1 2025.